{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:29:52Z","timestamp":1793312992093,"version":"4.5.0"},"reference-count":152,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ejphar.2025.177529","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T16:53:18Z","timestamp":1742403198000},"page":"177529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Oligonucleotide-based therapeutics for neurodegenerative disorders: Focus on antisense oligonucleotides"],"prefix":"10.1016","volume":"998","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7102-7305","authenticated-orcid":false,"given":"Heba M.","family":"Mansour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2074-8337","authenticated-orcid":false,"given":"Aiman S.","family":"El-Khatib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.177529_bib1","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1089\/hum.2014.086","article-title":"Translational and regulatory challenges for exon skipping therapies","volume":"25","author":"Aartsma-Rus","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ejphar.2025.177529_bib2","doi-asserted-by":"crossref","first-page":"7595","DOI":"10.1073\/pnas.88.17.7595","article-title":"Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice","volume":"88","author":"Agrawal","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9 24","key":"10.1016\/j.ejphar.2025.177529_bib3","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41576-023-00592-y","article-title":"Amyotrophic lateral sclerosis: translating genetic discoveries into therapies","volume":"24","author":"Ak\u00e7imen","year":"2023","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejphar.2025.177529_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102944","article-title":"Anti-\u03b1-synuclein ASO delivered to monoamine neurons prevents \u03b1-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys","volume":"59","author":"Alarc\u00f3n-Ar\u00eds","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejphar.2025.177529_bib5","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1124\/dmd.121.000418","article-title":"Adverse drug reactions and toxicity of the food and drug administration\u2013approved antisense oligonucleotide drugs","volume":"50","author":"Alhamadani","year":"2022","journal-title":"Drug Metabol. Dispos."},{"key":"10.1016\/j.ejphar.2025.177529_bib6","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nature22038","article-title":"Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice","volume":"544","author":"Becker","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2025.177529_bib7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","article-title":"Therapeutic antisense oligonucleotides are coming of age","volume":"70","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejphar.2025.177529_bib8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2025.177529_bib9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-neuro-070918-050501","article-title":"Antisense oligonucleotide therapies for neurodegenerative diseases","volume":"42","author":"Bennett Frank","year":"2019","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2025.177529_bib10","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s13311-022-01247-2","article-title":"Antisense oligonucleotides for the study and treatment of ALS","volume":"19","author":"Boros","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejphar.2025.177529_bib11","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/mt.2009.17","article-title":"Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice","volume":"17","author":"Boudreau","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejphar.2025.177529_bib12","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1093\/nar\/gkf651","article-title":"Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design","volume":"30","author":"Braasch","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2025.177529_bib13","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.neuroscience.2004.11.038","article-title":"Spinal distribution and metabolism of 2\u2019-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats","volume":"131","author":"Butler","year":"2005","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2025.177529_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.14802\/jmd.21006","article-title":"Gene therapy for Huntington's disease: the final strategy for a cure?","volume":"15","author":"Byun","year":"2021","journal-title":"J Mov Disord"},{"key":"10.1016\/j.ejphar.2025.177529_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25094809","article-title":"Antisense oligonucleotides (ASOs) in motor neuron diseases: a road to cure in light and shade","volume":"25","author":"Cantara","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"4 30","key":"10.1016\/j.ejphar.2025.177529_bib17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/ng854","article-title":"Disruption of an SF2\/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1","volume":"30","author":"Cartegni","year":"2002","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejphar.2025.177529_bib18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.biopha.2016.09.007","article-title":"In vivo proof-of-concept of removal of the huntingtin caspase cleavage motif-encoding exon 12 approach in the YAC128 mouse model of Huntington's disease","volume":"84","author":"Casaca-Carreira","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2025.177529_bib19","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/j.1742-4658.2009.06908.x","article-title":"Ribonuclease H: the enzymes in eukaryotes","volume":"276","author":"Cerritelli","year":"2009","journal-title":"FEBS J."},{"key":"10.1016\/j.ejphar.2025.177529_bib20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/978-1-61779-154-3_14","article-title":"SELEX (Systematic Evolution of Ligands by EXponential Enrichment), as a powerful tool for deciphering the protein-DNA interaction space","volume":"754","author":"Chai","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejphar.2025.177529_bib21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.omtn.2017.06.005","article-title":"Therapeutic miRNA and siRNA: moving from bench to clinic as next generation medicine","volume":"8","author":"Chakraborty","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejphar.2025.177529_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/genes10090705","article-title":"BACE1 inhibition using 2\u2019-OMePS steric blocking antisense oligonucleotides","volume":"10","author":"Chakravarthy","year":"2019","journal-title":"Genes"},{"key":"10.1016\/j.ejphar.2025.177529_bib23","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.ymthe.2018.02.029","article-title":"Targeting amyloid-\u03b2 precursor protein, APP, splicing with antisense oligonucleotides reduces toxic amyloid-\u03b2 production","volume":"26","author":"Chang","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejphar.2025.177529_bib24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuroscience.2007.01.008","article-title":"Antisense inhibition at the \u03b2-secretase-site of APP reduces cerebral amyloid and AChE activity in Tg2576","volume":"146","author":"Chauhan","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2025.177529_bib25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1089\/108729002761381320","article-title":"Trafficking of intracerebroventricularly injected antisense oligonucleotides in the mouse brain","volume":"12","author":"Chauthan","year":"2002","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"10.1016\/j.ejphar.2025.177529_bib26","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN Rx) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2025.177529_bib27","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.135633","article-title":"\u03b1-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease","volume":"6","author":"Cole","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejphar.2025.177529_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1304342","article-title":"Antisense oligonucleotides: a novel Frontier in pharmacological strategy","volume":"14","author":"Collotta","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177529_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci13101446","article-title":"Pharmacological therapies of spinal muscular atrophy: a narrative review of preclinical, clinical\u2013experimental, and real-world evidence","volume":"13","author":"Crisafulli","year":"2023","journal-title":"Brain Sci."},{"issue":"6 20","key":"10.1016\/j.ejphar.2025.177529_bib30","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: an overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2025.177529_bib31","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejphar.2025.177529_bib32","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41593-018-0236-8","article-title":"Animal models of neurodegenerative diseases","volume":"21","author":"Dawson","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejphar.2025.177529_bib33","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1126\/science.165.3898.1137","article-title":"Interferon induction increased through chemical modification of a synthetic polyribonucleotide","volume":"165","author":"De Clercq","year":"1969","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2025.177529_bib34","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1474-4422(15)00006-X","article-title":"Targeting \u03b1-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations","volume":"14","author":"Dehay","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2025.177529_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag0481","article-title":"Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy","volume":"9","author":"DeVos","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2025.177529_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9062004","article-title":"Antisense oligonucleotides: an emerging area in drug discovery and development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejphar.2025.177529_bib37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.euroneuro.2021.02.020","article-title":"A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders","volume":"48","author":"D\u00edaz-Caneja","year":"2021","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2025.177529_bib38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.omtn.2017.11.004","article-title":"A sensitive in vitro approach to assess the hybridization-dependent toxic potential of high affinity gapmer oligonucleotides","volume":"10","author":"Dieckmann","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejphar.2025.177529_bib39","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1002\/med.21706","article-title":"Therapeutic antisense oligonucleotides for movement disorders","volume":"41","author":"Doxakis","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejphar.2025.177529_bib40","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.omtn.2022.07.027","article-title":"Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies","volume":"29","author":"Easton","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejphar.2025.177529_bib41","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature09320","article-title":"Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS","volume":"466","author":"Elden","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2025.177529_bib42","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.bbi.2012.07.119","article-title":"95. Antisense directed against the amyloid precursor protein reduces cytokine expression in the brain and improves learning and memory in the Tg2576 mouse model of Alzheimer\u2019s disease","volume":"26","author":"Erickson","year":"2012","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.ejphar.2025.177529_bib163","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1742-2094-9-150","article-title":"Lipopolysaccharide impairs amyloid beta efflux from brain: altered vascular sequestration, cerebrospinal fluid reabsorption, peripheral clearance and transporter function at the blood\u2013brain barrier","volume":"9","author":"Erickson","year":"2012","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.ejphar.2025.177529_bib43","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3233\/JAD-2011-111517","article-title":"Peripheral administration of antisense oligonucleotides targeting the amyloid-\u03b2 protein precursor reverses A\u03b2PP and LRP-1 overexpression in the aged SAMP8 mouse brain","volume":"28","author":"Erickson","year":"2012","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2025.177529_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.22187","article-title":"Unveiling the potential of antisense oligonucleotides: mechanisms, therapies, and safety insights","volume":"85","author":"Ers\u00f6z","year":"2024","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejphar.2025.177529_bib45","author":"Estevez-Fraga"},{"key":"10.1016\/j.ejphar.2025.177529_bib46","first-page":"4","article-title":"Preventing Formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification","volume":"24","author":"Evers","year":"2014","journal-title":"nat"},{"key":"10.1016\/j.ejphar.2025.177529_bib47","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3233\/JAD-131883","article-title":"Central and peripheral administration of antisense oligonucleotide targeting amyloid precursor protein improves learning and memory and reduces neuroinflammatory cytokines in Tg2576 (APPswe) mice","volume":"40","author":"Farr","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.ejphar.2025.177529_bib48","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.freeradbiomed.2013.11.014","article-title":"Antisense oligonucleotide against GSK-3\u03b2 in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: involvement of transcription factor Nrf2 and implications for Alzheimer disease","volume":"67","author":"Farr","year":"2014","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejphar.2025.177529_bib49","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.3233\/JAD-160416","article-title":"Peripheral administration of GSK-3\u03b2 antisense oligonucleotide improves learning and memory in SAMP8 and Tg2576 mouse models of Alzheimer's disease","volume":"54","author":"Farr","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.ejphar.2025.177529_bib50","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.177529_bib51","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2025.177529_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2013.06.017","article-title":"Antisense directed against PS-1 gene decreases brain oxidative markers in aged senescence accelerated mice (SAMP8) and reverses learning and memory impairment: a proteomics study","volume":"65","author":"Fiorini","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejphar.2025.177529_bib53","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1021\/bi101208k","article-title":"Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat","volume":"49","author":"Gagnon","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejphar.2025.177529_bib54","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a024224","article-title":"Disease mechanisms of C9ORF72 repeat expansions","volume":"8","author":"Gendron","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.ejphar.2025.177529_bib55","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.tips.2021.04.010","article-title":"Overcoming the challenges of tissue delivery for oligonucleotide therapeutics","volume":"42","author":"G\u00f6kirmak","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2025.177529_bib56","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/mus.26001","article-title":"Making sense of antisense oligonucleotides: a narrative review","volume":"57","author":"Goyal","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejphar.2025.177529_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103691","article-title":"Antisense oligonucleotides for Alzheimer's disease therapy: from the mRNA to miRNA paradigm","volume":"74","author":"Grabowska-Pyrzewicz","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejphar.2025.177529_bib58","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/978-1-4939-2291-8_19","article-title":"The ViennaRNA web services","volume":"1269","author":"Gruber","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejphar.2025.177529_bib59","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.drudis.2017.09.018","article-title":"Locked nucleic acid: modality, diversity, and drug discovery","volume":"23","author":"Hagedorn","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejphar.2025.177529_bib60","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1215\/15228517-2007-052","article-title":"New therapeutic approach for brain tumors: intranasal delivery of telomerase inhibitor GRN163","volume":"10","author":"Hashizume","year":"2008","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejphar.2025.177529_bib61","doi-asserted-by":"crossref","first-page":"328","DOI":"10.15252\/emmm.201505846","article-title":"Therapeutic correction of ApoER2 splicing in Alzheimer's disease mice using antisense oligonucleotides","volume":"8","author":"Hinrich","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejphar.2025.177529_bib62","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1101\/gad.256644.114","article-title":"Motor neuron cell-nonautonomous rescue of spinal muscular atrophy phenotypes in mild and severe transgenic mouse models","volume":"29","author":"Hua","year":"2015","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejphar.2025.177529_bib63","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","article-title":"Antisense masking of an hnRNP A1\/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice","volume":"82","author":"Hua","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ejphar.2025.177529_bib64","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.neuron.2017.11.014","article-title":"Age-dependent effects of apoE reduction using antisense oligonucleotides in a model of \u03b2-amyloidosis","volume":"96","author":"Huynh","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.ejphar.2025.177529_bib65","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.omtn.2022.12.010","article-title":"Change of intracellular calcium level causes acute neurotoxicity by antisense oligonucleotides via CSF route","volume":"31","author":"Jia","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejphar.2025.177529_bib66","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.neuron.2016.04.006","article-title":"Gain of toxicity from ALS\/FTD-Linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs","volume":"90","author":"Jiang","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.ejphar.2025.177529_bib68","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1093\/nar\/gkw236","article-title":"The delivery of therapeutic oligonucleotides","volume":"44","author":"Juliano","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2025.177529_bib69","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejphar.2025.177529_bib70","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4068\/cmj.2020.56.2.87","article-title":"RNA therapy: current status and future potential","volume":"56","author":"Kim","year":"2020","journal-title":"Chonnam Med J"},{"issue":"9 24","key":"10.1016\/j.ejphar.2025.177529_bib71","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/gt.2017.32","article-title":"New treatments for serious conditions: ethical implications","volume":"24","author":"King","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.ejphar.2025.177529_bib72","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40478-015-0202-6","article-title":"FUS\/TLS deficiency causes behavioral and pathological abnormalities distinct from amyotrophic lateral sclerosis","volume":"3","author":"Kino","year":"2015","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.ejphar.2025.177529_bib73","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1093\/nar\/gkr089","article-title":"Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes","volume":"39","author":"Koller","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2025.177529_bib74","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"issue":"1 28","key":"10.1016\/j.ejphar.2025.177529_bib76","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-021-01615-z","article-title":"Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis","volume":"28","author":"Korobeynikov","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2025.177529_bib77","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood.V98.4.995","article-title":"The mononucleotide-dependent, nonantisense mechanism of action of phosphodiester and phosphorothioate oligonucleotides depends upon the activity of an ecto-5\u2019-nucleotidase","volume":"98","author":"Koziolkiewicz","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2025.177529_bib78","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1046\/j.1432-1033.2003.03555.x","article-title":"Antisense technologies","volume":"270","author":"Kurreck","year":"2003","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejphar.2025.177529_bib79","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1093\/nar\/30.9.1911","article-title":"Design of antisense oligonucleotides stabilized by locked nucleic acids","volume":"30","author":"Kurreck","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2025.177529_bib80","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.celrep.2013.10.049","article-title":"Hexanucleotide repeats in ALS\/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic","volume":"5","author":"Lee","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejphar.2025.177529_bib81","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1002\/med.21718","article-title":"Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson's disease in the precision medicine era","volume":"40","author":"Li","year":"2020","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejphar.2025.177529_bib82","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1093\/nar\/gkv143","article-title":"Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages","volume":"43","author":"Liang","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2025.177529_bib83","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.neuron.2013.07.033","article-title":"Converging mechanisms in als and FTD: disrupted RNA and protein homeostasis","volume":"79","author":"Ling","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.ejphar.2025.177529_bib84","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.omtn.2022.04.007","article-title":"Preclinical evaluation of WVE-004, aninvestigational stereopure oligonucleotide forthe treatment of C9orf72-associated ALS or FTD","volume":"28","author":"Liu","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejphar.2025.177529_bib85","article-title":"Variant-selective stereopure oligonucleotides protect against pathologies associated with C9orf72-repeat expansion in preclinical models","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2025.177529_bib86","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","author":"MacDonald","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2025.177529_bib87","first-page":"275","article-title":"Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics","volume":"2","author":"Mansoor","year":"2008","journal-title":"Gene Regul. Syst. Biol."},{"key":"10.1016\/j.ejphar.2025.177529_bib88","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/B978-0-443-18677-6.00010-5","article-title":"Repositioning of receptor tyrosine kinase inhibitors: from cancer to neurodegenerative and psychiatric disorders","author":"Mansour","year":"2023","journal-title":"Recep. Tyros. Kin. Neurodegen. Psychiat. Disord."},{"key":"10.1016\/j.ejphar.2025.177529_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101841","article-title":"Kinases control of regulated cell death revealing druggable targets for Parkinson's disease","volume":"85","author":"Mansour","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.ejphar.2025.177529_bib90","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.4103\/1673-5374.332132","article-title":"Repurposed anti-cancer epidermal growth factor receptor inhibitors: mechanisms of neuroprotective effects in Alzheimer's disease","volume":"17","author":"Mansour","year":"2022","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.ejphar.2025.177529_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2021.113697","article-title":"Lapatinib ditosylate rescues memory impairment in D-galactose\/ovariectomized rats: potential repositioning of an anti-cancer drug for the treatment of Alzheimer's disease","volume":"341","author":"Mansour","year":"2021","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2025.177529_bib92","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/978-3-319-71779-1_20","article-title":"Gene therapies for polyglutamine diseases","volume":"1049","author":"Matos","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejphar.2025.177529_bib93","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1172\/JCI99081","article-title":"Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models","volume":"128","author":"McCampbell","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2025.177529_bib95","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.molcel.2004.07.007","article-title":"Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs","volume":"15","author":"Meister","year":"2004","journal-title":"Mol Cell"},{"key":"10.1016\/j.ejphar.2025.177529_bib96","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2025.177529_bib97","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","article-title":"Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"21","author":"Mercuri","year":"2022","journal-title":"Lancet Neurol."},{"issue":"1 8","key":"10.1016\/j.ejphar.2025.177529_bib98","first-page":"1","article-title":"Spinal muscular atrophy","volume":"8","author":"Mercuri","year":"2022","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"2","key":"10.1016\/j.ejphar.2025.177529_bib99","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2003715","article-title":"Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS","volume":"383","author":"Miller","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ejphar.2025.177529_bib101","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2025.177529_bib103","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","article-title":"An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study","volume":"12","author":"Miller","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2025.177529_bib105","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00401-013-1189-3","article-title":"Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins","volume":"126","author":"Mori","year":"2013","journal-title":"Acta Neuropathol."},{"issue":"6 29","key":"10.1016\/j.ejphar.2025.177529_bib106","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","article-title":"Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial","volume":"29","author":"Mummery","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2025.177529_bib107","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1172\/JCI45364","article-title":"The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease","volume":"121","author":"Munoz-Sanjuan","year":"2011","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2025.177529_bib108","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/genes8060157","article-title":"Ataxin-2: from RNA control to human health and disease","volume":"8","author":"Ostrowski","year":"2017","journal-title":"Genes"},{"issue":"1 14","key":"10.1016\/j.ejphar.2025.177529_bib109","first-page":"1","article-title":"Application of antisense oligonucleotide drugs in amyotrophic lateral sclerosis and Huntington's disease","volume":"14","author":"Ou","year":"2025","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.ejphar.2025.177529_bib110","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001777","article-title":"Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy","volume":"3","author":"Passini","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2025.177529_bib111","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/WNO0b013e3181b416de","article-title":"The spinocerebellar ataxias","volume":"29","author":"Paulson","year":"2009","journal-title":"J. Neuro Ophthalmol."},{"key":"10.1016\/j.ejphar.2025.177529_bib112","doi-asserted-by":"crossref","first-page":"8107","DOI":"10.1093\/nar\/gkac618","article-title":"Insights into innate immune activation via PS-ASO\u2013protein\u2013TLR9 interactions","volume":"50","author":"Pollak","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2025.177529_bib113","doi-asserted-by":"crossref","DOI":"10.1002\/wrna.1594","article-title":"The powerful world of antisense oligonucleotides: from bench to bedside","volume":"11","author":"Quemener","year":"2020","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"10.1016\/j.ejphar.2025.177529_bib114","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27020536","article-title":"Small drugs, huge impact: the extraordinary impact of antisense oligonucleotides in research and drug development","volume":"27","author":"Quemener","year":"2022","journal-title":"Molecules"},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2025.177529_bib115","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/jnc.13625","article-title":"Physiological functions and pathobiology of TDP-43 and FUS\/TLS proteins","volume":"138","author":"Ratti","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2025.177529_bib116","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/ng0596-43","article-title":"Motor neurons in Cu\/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury","volume":"13","author":"Reaume","year":"1996","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejphar.2025.177529_bib117","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1124\/jpet.113.212407","article-title":"Pharmacology of a central nervous system delivered 2\u2032-O-Methoxyethyl\u2013Modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates","volume":"350","author":"Rigo","year":"2014","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2025.177529_bib118","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s004390100473","article-title":"SMN gene duplication and the emergence of the SMN2 gene occurred in distinct hominids: SMN2 is unique to Homo sapiens","volume":"108","author":"Rochette","year":"2001","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ejphar.2025.177529_bib119","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3233\/JHD-190001","article-title":"Huntington's disease clinical trials corner: january 2019","volume":"8","author":"Rodrigues","year":"2019","journal-title":"J Huntingtons Dis"},{"key":"10.1016\/j.ejphar.2025.177529_bib120","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1101\/gad.197418.112","article-title":"TSUNAMI: an antisense method to phenocopy splicing-associated diseases in animals","volume":"26","author":"Sahashi","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejphar.2025.177529_bib121","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cbpa.2018.05.018","article-title":"Therapeutic strategies for targeting neurodegenerative protein misfolding disorders","volume":"44","author":"Scannevin","year":"2018","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejphar.2025.177529_bib122","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.637548","article-title":"Emerging perspectives on dipeptide repeat proteins in C9ORF72 ALS\/FTD","volume":"15","author":"Schmitz","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ejphar.2025.177529_bib123","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.neuron.2017.04.010","article-title":"Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases","volume":"94","author":"Schoch","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.ejphar.2025.177529_bib124","doi-asserted-by":"crossref","first-page":"9920","DOI":"10.1073\/pnas.94.18.9920","article-title":"Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos","volume":"94","author":"Schrank","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejphar.2025.177529_bib125","doi-asserted-by":"crossref","DOI":"10.3390\/v11050448","article-title":"Antiviral RNAi in insects and mammals: parallels and differences","volume":"11","author":"Schuster","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.ejphar.2025.177529_bib126","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1371\/journal.pgen.0020140","article-title":"Designing siRNA that distinguish between genes that differ by a single nucleotide","volume":"2","author":"Schwarz","year":"2006","journal-title":"PLoS Genet."},{"key":"10.1016\/j.ejphar.2025.177529_bib127","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10465","article-title":"ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function","volume":"7","author":"Sharma","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2025.177529_bib128","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","article-title":"Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs","volume":"46","author":"Shen","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2025.177529_bib129","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nm.4490","article-title":"Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS\/FTD human induced motor neurons","volume":"24","author":"Shi","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ejphar.2025.177529_bib130","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/brain\/awz328","article-title":"Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders","volume":"143","author":"Silva","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2025.177529_bib132","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1128\/MCB.26.4.1333-1346.2006","article-title":"Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron","volume":"26","author":"Singh","year":"2006","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2025.177529_bib133","doi-asserted-by":"crossref","first-page":"8144","DOI":"10.1093\/nar\/gkt609","article-title":"An intronic structure enabled by a long-distance interaction serves as a novel target for splicing correction in spinal muscular atrophy","volume":"41","author":"Singh","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2025.177529_bib134","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI25424","article-title":"Antisense oligonucleotide therapy for neurodegenerative disease","volume":"116","author":"Smith","year":"2006","journal-title":"J. Clin. Investig."},{"issue":"7601 533","key":"10.1016\/j.ejphar.2025.177529_bib135","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nature17939","article-title":"Parkinson-associated risk variant in distal enhancer of \u03b1-synuclein modulates target gene expression","volume":"533","author":"Soldner","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2025.177529_bib136","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3233\/JHD-130057","article-title":"Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease","volume":"2","author":"Stanek","year":"2013","journal-title":"J Huntingtons Dis"},{"key":"10.1016\/j.ejphar.2025.177529_bib137","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1093\/nar\/gkq457","article-title":"Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates","volume":"38","author":"Straarup","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2025.177529_bib138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-6817-6_1","article-title":"Invention and early history of morpholinos: from pipe dream to practical products","volume":"1565","author":"Summerton","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejphar.2025.177529_bib139","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.omtm.2020.09.003","article-title":"Investigational assay for haplotype phasing of the huntingtin gene","volume":"19","author":"Svrzikapa","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ejphar.2025.177529_bib140","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/nar\/gkl1071","article-title":"Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals","volume":"35","author":"Swayze","year":"2007","journal-title":"Nucleic Acids Res."},{"issue":"24","key":"10.1016\/j.ejphar.2025.177529_bib141","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Phase 1\u20132a IONIS-HTTRx Study Site Teams. Targeting Huntingtin Expression in Patients with Huntington's Disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2025.177529_bib143","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature20413","article-title":"Decoding ALS: from genes to mechanism","volume":"539","author":"Taylor","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2025.177529_bib144","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41591-021-01557-6","article-title":"Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide","volume":"28","author":"Tran","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ejphar.2025.177529_bib146","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/B978-0-443-18677-6.00015-4","article-title":"Protein kinase inhibitors as therapeutics in neurodegenerative and psychiatric disorders: progress, challenges, and recommendations","author":"Tridente","year":"2023","journal-title":"Recep. Tyros. Kin. Neurodegen. Psychiat. Disord."},{"key":"10.1016\/j.ejphar.2025.177529_bib147","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.molmed.2023.12.003","article-title":"The sense of antisense therapies in ALS","volume":"30","author":"Van Daele","year":"2024","journal-title":"Trends Mol. Med."},{"issue":"12 53","key":"10.1016\/j.ejphar.2025.177529_bib148","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41588-021-00973-1","article-title":"Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology","volume":"53","author":"van Rheenen","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejphar.2025.177529_bib149","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1093\/hmg\/ddt117","article-title":"ALS mutant FUS disrupts nuclear localization and sequesters wild-type FUS within cytoplasmic stress granules","volume":"22","author":"Vance","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejphar.2025.177529_bib150","doi-asserted-by":"crossref","first-page":"7108","DOI":"10.1074\/jbc.M210326200","article-title":"Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis","volume":"278","author":"Vickers","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2025.177529_bib151","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.xphs.2024.04.021","article-title":"A review on commercial oligonucleotide drug products","volume":"113","author":"Vinjamuri","year":"2024","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.ejphar.2025.177529_bib152","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1093\/nar\/gku184","article-title":"Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides","volume":"42","author":"Ward","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2025.177529_bib153","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1073\/pnas.90.10.4665","article-title":"Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system","volume":"90","author":"Whitesell","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1 2","key":"10.1016\/j.ejphar.2025.177529_bib154","first-page":"1","article-title":"Aptamer technology for tracking cells' status & function","volume":"2","author":"Wiraja","year":"2014","journal-title":"Mole. Cell. Therap."},{"key":"10.1016\/j.ejphar.2025.177529_bib155","doi-asserted-by":"crossref","first-page":"17181","DOI":"10.1074\/jbc.M311683200","article-title":"Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs","volume":"279","author":"Wu","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"9 24","key":"10.1016\/j.ejphar.2025.177529_bib156","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/gt.2017.64","article-title":"Development of gene therapies\u2014lessons from nusinersen","volume":"24","author":"Xu","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.ejphar.2025.177529_bib157","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/B978-0-443-18677-6.00007-5","article-title":"The molecular pathology of neurodegenerative and psychiatric disorders","author":"Yan","year":"2023","journal-title":"Recep. Tyros. Kin. Neurodegen. Psychiat. Disord."},{"key":"10.1016\/j.ejphar.2025.177529_bib159","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1073\/pnas.75.1.280","article-title":"Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide","volume":"75","author":"Zamecnik","year":"1978","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2025.177529_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114432","article-title":"The growth of siRNA-based therapeutics: updated clinical studies","volume":"189","author":"Zhang","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177529_bib161","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.omtn.2017.08.002","article-title":"LRRK2 antisense oligonucleotides ameliorate \u03b1-synuclein inclusion formation in a Parkinson's disease mouse model","volume":"8","author":"Zhao","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejphar.2025.177529_bib162","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","article-title":"Molecular mechanisms and potential therapeutical targets in Huntington's disease","volume":"90","author":"Zuccato","year":"2010","journal-title":"Physiol. Rev."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925002833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925002833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T08:48:50Z","timestamp":1746953330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925002833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":152,"alternative-id":["S0014299925002833"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177529","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oligonucleotide-based therapeutics for neurodegenerative disorders: Focus on antisense oligonucleotides","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177529","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"177529"}}